Description: ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.
Home Page: ars-pharma.com
SPRY Technical Analysis
11682 El Camino Real
San Diego,
CA
92130
United States
Phone:
858 771 9307
Officers
| Name | Title |
|---|---|
| Mr. Richard Lowenthal M.B.A., M.S., MSMSEL | Founder, President, CEO & Director |
| Dr. Sarina Tanimoto M.B.A., M.D. | Co-Founder & Chief Medical Officer |
| Mr. Alexander A. Fitzpatrick Esq. | Chief Legal Officer & Secretary |
| Dr. Robert Bell Ph.D. | Co-Founder & Chief Science Officer |
| Ms. Kathleen D. Scott CPA | Chief Financial Officer |
| Mr. Brian T. Dorsey M.S. | Chief Operations Officer |
| Mr. Daniel Relovsky | Senior Vice President of Marketing |
| Mr. Harris Kaplan M.B.A. | Executive Vice President of Commercial Strategy |
| Mr. Eric Karas | Chief Commercial Officer |
| Mr. Justin Chakma | Chief Business Officer & Secretary |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 6.1122 |
| Price-to-Sales TTM: | 478.3586 |
| IPO Date: | 2020-12-04 |
| Fiscal Year End: | December |
| Full Time Employees: | 24 |